ASH Clinical News November 2015 | Page 5
B:16.75”
T:16.25”
S:14.625”
Bronchitis
eported (< 1%) in patients
ransaminases. Monitor liver
ate.
5 (1%)
39 (10%)
2 (1%)
54 (14%)
35 (9%)
43 (11%)
27 (7%)
Hypokalemia
78 (20%)
22 (6%)
35 (9%)
12 (3%)
Hypocalcemia
55 (14%)
10 (3%)
39 (10%)
5 (1%)
Hyperglycemia
43 (11%)
18 (5%)
33 (9%)
15 (4%)
88 (22%)
3 (1%)
73 (19%)
3 (1%)
43 (11%)
7 (2%)
37 (10%)
4 (1%)
63 (16%)
6 (2%)
50 (13%)
8 (2%)
Pneumonia
Metabolism and Nutrition Disorders
remic Syndrome (TTP/HUS)
eported in patients who received
Discontinue Kyprolis if TTP/
HUS is excluded, Kyprolis may
n patients previously experiencing
Musculoskeletal and Connective Tissue Disorders
Muscle Spasms
S)
gnant woman based on its
o adequate and well-controlled
ve and can be found the Warning
de cardiac toxicities, acute kidney
dyspnea, hypertension, venous
c toxicity and hepatic failure,
g conditions, adverse reaction
ectly compared with rates in the
s observed in medical practice.
127 (33%)
47 (12%)
7%)
115 (30%)
89 (23%)
%)
75 (19%)
39 (10%)
105 (27%)
12 (3%)
1 (0%)
46 (12%)
0
Dyspneac
70 (18%)
9 (2%)
58 (15%)
6 (2%)
45 (12%)
5 (1%)
53 (14%)
5 (1%)
Embolic and Thrombotic Events,
Venousd
49 (13%)
16 (4%)
22 (6%)
9 (2%)
Hypertensione
41 (11%)
12 (3%)
15 (4%)
4 (1%)
Vascular Disorders
KRd = Kyprolis, lenalidomide, and low-dose dexamethasone; Rd = lenalidomide and low-dose
dexamethasone
a
Pneumonia includes preferred terms of pneumonia, bronchopneumonia
b
Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC
c
Dyspnea includes preferred terms of dyspnea, dyspnea exertional
d
Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope
search of embolic and thrombotic events, venous.
e
Hypertension includes preferred terms of hypertension, hypertensive crisis, hypertensive emergency
Laboratory Abnormalities
KRd
(N = 392)
Rd
(N = 389)
182 (46%)
119 (31%)
Decreased Absolute Neutrophil Count
152 (39%)
140 (36%)
FV7&V6VB